EHA 2023 Actero Sponsorship

EHA 2023

Actero company sponsored hematology oncology specialists in European Hematology Association, Being one of the most important event in the field of hematology in order to have more access to the latest scientific update.

Xalico

Xalico actero pharma

How to use Xalico: Administer Xalico in combination with fluorouracil and leucovorin every 2 weeks. For adjuvant treatment, continue treatment for up to 12 cycles or unacceptable toxicity.  For advanced colorectal cancer, continue treatment until disease progression or unacceptable toxicity. Day 1 Administer Xalico 85 mg/m2 as an intravenous infusion over 120 minutes and leucovorin […]

Evacim

Evacim actero pharma

How to use Evacim: Administer only as an intravenous (IV) infusion. Do not administer as an intravenous push or bolus. Do not initiate Evacim until at least 28 days following major surgery. Administer Evacim after the surgical incision has fully healed. First infusion: Administer infusion over 90 minutes. ·Subsequent infusions: Administer second infusion over 60 […]

Lipaxol

Lipaxol actero pharma

How to use Lipaxol : Recommended Dosage for Metastatic Breast Cancer After failure of combination chemotherapy for metastatic breast cancer or relapse within 6 months of adjuvant chemotherapy, the recommended regimen for Lipaxol is 260 mg/m2 administered intravenously over 30 minutes every 3 weeks. for Non-Small Cell Lung Cancer The recommended dose of Lipaxol is […]

Onkotaxel

Onkotaxel Actero pharma

How to use Onkotaxel: Onkotaxel  is a cytotoxic anticancer drug and, as with other potentially toxic compounds, caution should be exercised when handling and preparing Onkotaxel solutions. The use of gloves is recommended. If Onkotaxel  initial diluted solution, or final dilution for infusion should come into contact with the skin, immediately and thoroughly wash with […]

Rinteca

Rinteca 100 Actero Pharma

How to use Rinteca Administer Rinteca as a 90-minute intravenous infusion followed by LV and 5-FU. A reduction in the starting dose by one dose level of Rinteca may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin […]